Gleevec, a cancer drug that costs US$70,000 in the U.S. per year, cost just US$2,500 in India because it can’t be patented there.
India’s Supreme Court, in a landmark decision on April 1 (2013), refused an appeal from Novartis of Basel to extend patent protection for its leukemia drug Gleevec or Glivec (imatinib).